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Background: Evidence suggests that obesity increases the risk of cardiovascular disease due to chronic kidney disease (CKD). This sub-analysis 
of the TNT study determined the frequency of CKD in CHD patients with obesity, analyzed the effect of CKD on major CV events (MCVE) in these 
subjects, and examined’the effect of intensive lipid lowering with atorvastatin (ATV) 80 mg on the incidence of MCVE (CHD death, nonfatal MI, 
resuscitated cardiac arrest, or stroke) compared with ATV 10 mg in stable coronary patients with obesity and CKD.
Methods: Following 8 weeks’ open-label therapy with ATV 10 mg, 10,001 CHD patients were randomized to double-blind therapy with ATV 10 mg or 
80 mg for a follow-up of 4.9 years. Obesity was defined as BMI ≥30 kg/m2 and CKD as a glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2 
using the modified 4 component MDRD equation.
Results: Prevalence of CKD was similar in subjects with (33.1%) vs those without obesity (31.7%) in the 9500 patients who had complete renal 
data. In the CKD subgroup, the rate of MCVE was significantly higher among obese vs non-obese patients (HR=1.59, 95% CI 1.26-2.01; P<0.0001). 
In patients without CKD, the presence of obesity had no significant difference on event rates (P=0.15). Patients with both obesity and CKD were at 
greater risk of MCVE than those with either condition alone and significantly greater risk than those with neither condition (HR=1.92, 95% CI 1.55-
2.36; P<0.0001). ATV 80 mg significantly reduced the risk of MCVE vs ATV 10 mg in all CKD and obesity cross-classification categories except the 
subgroup with obesity alone. The largest treatment effect was observed in those CHD patients with obesity and CKD, for whom the relative risk of 
MCVE was significantly reduced by 32.5% with ATV 80 mg vs 10 mg (HR=0.675, 95% CI 0.49-0.97; P=0.03).
Conclusion: Obesity is an important co-morbidity that contributes to additional CV risk in CKD patients with CHD. High-dose ATV 80 mg 
significantly reduced the incidence of MCVE, compared with ATV 10 mg in coronary patients with obesity and CKD.
